**Introduction**

Preeclampsia and eclampsia are serious complications of pregnancy characterized by new-onset hypertension and seizures, respectively. Preeclampsia affects 2-8% of pregnancies worldwide and, together with eclampsia, remains a leading cause of maternal and fetal morbidity and mortality. As pharmacists, early recognition and appropriate management of preeclampsia and eclampsia are critical skills.

Preeclampsia manifests as hypertension along with signs of end-organ dysfunction, most commonly proteinuria. It can rapidly progress to eclampsia, which consists of seizures in a woman with preeclampsia. Timely diagnosis of preeclampsia followed by proper monitoring and treatment is key to preventing maternal seizures and other life-threatening complications. However, diagnosis can be challenging as symptoms may be subtle initially and mimic normal pregnancy physiological changes.

Recent research has focused on risk stratification through biomarkers and clinical prediction models to identify women at highest risk for progression. The pharmacist plays a vital role in recognizing warning signs, assisting with medication selection and dosing, and monitoring response. This section will cover pathophysiology, diagnosis, medications for seizure prophylaxis and blood pressure management, and overall implications for the mother and fetus. We will also discuss recent updates in prediction tools and ongoing controversies regarding optimal blood pressure targets in this high-risk population.

**Clinical Presentation**

Preeclampsia is a hypertensive disorder that occurs during pregnancy, typically after 20 weeks of gestation. It is characterized by high blood pressure and evidence of organ damage, most commonly affecting the kidneys and liver. If left untreated, preeclampsia can progress to eclampsia, which is characterized by the development of seizures.

Typical Signs and Symptoms of Preeclampsia and Eclampsia:

* High blood pressure (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg)
* Proteinuria (excretion of ≥0.3 grams of protein in a 24-hour urine collection or ≥1+ on urine dipstick)
* Edema (swelling of the hands, face, or legs)
* Headache, often severe and persistent
* Visual disturbances, such as blurred vision or seeing flashing lights
* Abdominal pain, particularly in the upper right quadrant
* Nausea and vomiting
* Shortness of breath
* Decreased urine output
* Changes in blood clotting, resulting in easy bruising or bleeding

Risk Factors for Preeclampsia and Eclampsia:

* First pregnancy (primiparity)
* Age extremes (teenage pregnancy or pregnancy over 35 years)
* Multiple gestations (twins, triplets, etc.)
* History of preeclampsia/eclampsia in a previous pregnancy
* Family history of preeclampsia/eclampsia
* Preexisting medical conditions, such as chronic hypertension, diabetes, kidney disease, or autoimmune disorders
* Obesity
* Assisted reproductive techniques (IVF)
* African American ethnicity

Common Pitfalls or Misdiagnoses:

* Preeclampsia can sometimes present with subtle or atypical symptoms, leading to a delay in diagnosis or misdiagnosis.
* Symptoms such as headache, nausea, and swelling can be attributed to normal pregnancy discomfort, leading to underestimation of the severity of the condition.
* The absence of proteinuria does not exclude the diagnosis of preeclampsia, as it is not always present in all cases.
* Symptoms may overlap with other conditions, such as migraine, gastroenteritis, or normal pregnancy-related complaints, leading to misdiagnosis.

Clinical Insights:

* Regular blood pressure monitoring and urine protein testing are essential for early detection and diagnosis of preeclampsia.
* Risk assessment during prenatal care visits can help identify women at higher risk for developing preeclampsia.
* Prompt initiation of treatment and close monitoring of blood pressure and organ function are crucial to prevent complications and manage the condition effectively.
* Multidisciplinary care involving obstetricians, maternal-fetal medicine specialists, and other healthcare providers is important for the optimal management of preeclampsia and eclampsia.

In summary, preeclampsia and eclampsia are serious conditions that can have significant implications for both the mother and the baby. Recognizing the signs and symptoms, understanding the risk factors, and ensuring appropriate monitoring and management are key to providing optimal care for affected patients.

**Pathophysiology**

Preeclampsia Pathophysiology

* The exact mechanisms underlying preeclampsia are not fully understood, but are thought to involve placental and vascular factors.
* During normal pregnancy, cytotrophoblasts invade and modify the maternal uterine spiral arteries, converting them from small muscular vessels to high-capacity conduits. This facilitates increased blood flow to support the fetus.
* In preeclampsia, cytotrophoblast invasion is shallow and results in narrowed, high-resistance spiral arteries. This leads to placental ischemia/hypoxia.
* The under-perfused placenta releases factors into maternal circulation that damage vascular endothelium and cause systemic inflammation. Key mediators implicated include:
  + Anti-angiogenic proteins like soluble fms-like tyrosine kinase-1 (sFlt-1)
  + Inflammatory cytokines
  + Oxidative stress
  + Autoantibodies against angiotensin receptors
* This widespread endothelial dysfunction underlies the clinical manifestations of preeclampsia:
  + Hypertension
  + Proteinuria
  + Edema
  + Thrombocytopenia
  + Liver dysfunction

Progression to Eclampsia

* Cerebral autoregulation is altered in preeclampsia, with loss of ability to maintain stable cerebral blood flow over a range of blood pressures.
* As a result, episodes of severe hypertension can lead to cerebral edema, ischemia, and breakthrough seizures known as eclampsia.
* Other proposed contributors to seizure activity include cerebral vasospasm, hyponatremia, and endothelial dysfunction.
* Once seizures develop, further brain injury can occur from hypoxia and metabolic derangements during continued seizures.

In summary, preeclampsia stems from abnormal placentation and an exaggerated maternal systemic response. Dysregulated cerebral blood flow and autoregulation allow hypertension to trigger eclamptic seizures and associated neurological sequelae. Understanding this complex interplay of vascular, placental, and inflammatory factors provides insights into the origins and progression of this dangerous complication of pregnancy.

**Diagnostic Approach**

The diagnosis of preeclampsia and eclampsia is primarily based on a combination of clinical signs and symptoms, along with objective laboratory findings. The diagnostic approach involves a comprehensive evaluation of the patient's medical history, physical examination, and laboratory tests. The following are key components of the diagnostic approach:

1. Medical History:
   * Inquire about the patient's gestational age, symptoms, and any previous history of hypertension or preeclampsia in prior pregnancies.
   * Assess the presence of risk factors such as primiparity, advanced maternal age, multiple gestations, preexisting medical conditions, and family history of preeclampsia/eclampsia.
2. Physical Examination:
   * Measure blood pressure using a properly sized cuff and assess for any signs of hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg).
   * Evaluate for signs of end-organ damage, including visual disturbances, headache, epigastric pain, edema, and decreased urine output.
   * Assess general well-being and signs of fetal distress.
3. Laboratory Tests:
   * Blood tests: Measure complete blood count (CBC) to assess for thrombocytopenia, liver function tests (LFTs) to evaluate liver involvement, and renal function tests to monitor kidney function.
   * Urine tests: Assess for proteinuria through a 24-hour urine collection or a spot urine protein-to-creatinine ratio.
   * Coagulation profile: Check for evidence of disseminated intravascular coagulation (DIC) or abnormal clotting parameters.
   * Serum uric acid levels: Elevated levels may indicate impaired renal function and contribute to the diagnostic criteria.
   * Other tests: Depending on the clinical presentation and severity, additional tests such as fetal ultrasound, Doppler studies, and fetal heart rate monitoring may be performed to assess fetal well-being.

Diagnostic Criteria for Preeclampsia:

* Hypertension: Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, on two separate occasions at least 4 hours apart.
* Proteinuria: ≥0.3 grams of protein in a 24-hour urine collection or ≥1+ on urine dipstick.
* In the absence of proteinuria, the presence of new-onset hypertension with associated end-organ damage (e.g., thrombocytopenia, abnormal liver function, renal insufficiency, pulmonary edema, or visual disturbances) can also contribute to the diagnosis.

Diagnostic Criteria for Eclampsia:

* Presence of seizures in a woman with preeclampsia that cannot be attributed to other causes.
* Seizures typically present as generalized tonic-clonic convulsions.

Interpretation of Diagnostic Tests:

* Blood pressure: Consistently elevated blood pressure readings help establish the diagnosis of preeclampsia.
* Proteinuria: Urine protein levels ≥0.3 grams in a 24-hour collection or ≥1+ on urine dipstick indicate proteinuria.
* Laboratory tests: Abnormalities in liver function tests, renal function tests, and coagulation profile support the diagnosis of preeclampsia and help assess end-organ involvement.
* Serum uric acid levels: Elevated levels may suggest impaired renal function and contribute to the diagnostic criteria.

Differentiating Subtypes:

* Severe preeclampsia: Additional criteria may include severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg), severe proteinuria, evidence of end-organ damage, fetal growth restriction, or symptoms of severe headache or visual disturbances.
* HELLP syndrome: Diagnosed when there is evidence of hemolysis, elevated liver enzymes, and low platelet count in the setting of preeclampsia.

In summary, the diagnosis of preeclampsia and eclampsia is based on a combination of clinical evaluation and laboratory tests. Blood pressure measurements, assessment of proteinuria, and evaluation of end-organ involvement are essential components of the diagnostic approach. Prompt recognition and appropriate management are crucial to prevent complications and ensure the best outcomes for both the mother and the baby.

**Management – Overview**

The management of preeclampsia and eclampsia aims to control blood pressure, prevent seizures, and mitigate the risks to both the mother and the fetus. The following are key principles and strategies in the management of these conditions:

1. Blood Pressure Control:
   * Antihypertensive medications are used to maintain blood pressure within a target range to prevent complications. First-line agents include labetalol and hydralazine, which are safe and effective in pregnancy.
   * Alternative antihypertensive options may include nifedipine, methyldopa, or prazosin, depending on individual patient characteristics and response to treatment.
2. Seizure Prevention:
   * Magnesium sulfate is the drug of choice for preventing and treating seizures in preeclampsia and eclampsia. It acts as a central nervous system depressant and neuroprotective agent.
   * Magnesium sulfate is administered as an intravenous bolus followed by maintenance infusion. It helps prevent recurrent seizures and has shown to reduce the risk of maternal death and other adverse outcomes.
3. Fetal Monitoring:
   * Regular fetal surveillance is essential to assess fetal well-being and determine the optimal timing of delivery.
   * Monitoring techniques may include fetal ultrasound, Doppler studies, and fetal heart rate monitoring to assess fetal growth, amniotic fluid volume, and placental function.
4. Delivery Timing:
   * The decision for delivery is based on several factors, including gestational age, severity of the disease, maternal condition, and fetal well-being.
   * In severe cases or when complications arise, early delivery may be necessary to prevent further deterioration. In less severe cases, expectant management with close monitoring may be appropriate to allow for fetal maturation.
5. Non-pharmacological Interventions:
   * Bed rest and activity restriction may be recommended in certain cases to reduce blood pressure and prevent complications.
   * Adequate hydration and a well-balanced diet are important to support overall maternal health.
   * Regular prenatal care and close follow-up with healthcare providers are crucial to monitor blood pressure, proteinuria, and other signs of disease progression.

**Pharmacotherapy**

Initial Management:

1. Magnesium Sulfate:

* Mechanism of Action: Magnesium sulfate acts as a central nervous system depressant and anticonvulsant. It antagonizes calcium influx into neurons, reducing neuronal excitability.
* Dosing: The loading dose is typically 4-6 grams administered intravenously over 15-20 minutes. Maintenance therapy is given as an intravenous infusion at a rate of 1-4 grams per hour.
* Side Effects: Common side effects include flushing, warmth, and lethargy. Higher doses can cause respiratory depression, hypotension, and loss of deep tendon reflexes. Magnesium toxicity can lead to cardiac arrhythmias, cardiac arrest, and respiratory paralysis.
* Contraindications: Magnesium sulfate should be used cautiously in patients with renal insufficiency or myasthenia gravis.
* Monitoring Parameters: Continuous monitoring of respiratory rate, blood pressure, reflexes, urine output, and magnesium levels is essential. Serum magnesium levels should be maintained between 4-7 mEq/L.
* Clinical Pearls: Magnesium sulfate should be administered by an infusion pump to ensure accurate dosing. Calcium gluconate should be readily available as an antidote for magnesium toxicity.

1. Antihypertensive Therapy:

* Labetalol: A non-selective beta-blocker with alpha-1 receptor blocking properties.
  + Mechanism of Action: Labetalol reduces blood pressure by decreasing peripheral vascular resistance and cardiac output.
  + Dosing: The initial intravenous dose is typically 20 mg, followed by repeat doses of 40-80 mg every 10 minutes, up to a maximum dose of 300 mg.
  + Side Effects: Common side effects include bradycardia, hypotension, dizziness, and fatigue. It should be used cautiously in patients with asthma or heart block.
  + Monitoring Parameters: Blood pressure, heart rate, and signs of hypotension should be closely monitored.
  + Clinical Pearls: Labetalol can be administered orally for maintenance therapy after blood pressure is stabilized.

1. Nicardipine:

* Mechanism of Action: calcium channel blocker that inhibits calcium influx into smooth muscle cells, resulting in vasodilation.
* Dosing: 5-15 mg/hr, titrate by 2.5 mg evert 5-15 minutes with a max of 15 mg/hr
* Side Effects: Common side effects include headache, flushing, dizziness, and peripheral edema. It should be used cautiously in patients with congestive heart failure or hypotension.
* Monitoring Parameters: Blood pressure, heart rate, and signs of hypotension should be closely monitored.
* Mechanism of Action: Nifedipine is a calcium channel blocker that inhibits calcium influx into smooth muscle cells, resulting in vasodilation.
* Dosing: Immediate-release nifedipine can be given orally as 10-20 mg every 4-6 hours, up to a maximum of 120 mg per day. Extended-release formulations are also available.
* Side Effects: Common side effects include headache, flushing, dizziness, and peripheral edema. It should be used cautiously in patients with congestive heart failure or hypotension.
* Monitoring Parameters: Blood pressure, heart rate, and signs of hypotension should be closely monitored.
* Clinical Pearls: Nifedipine is not recommended for acute blood pressure control in hypertensive emergencies due to the risk of profound hypotension.

* Hydralazine: A direct-acting vasodilator that primarily affects arteriolar smooth muscle.
  + Mechanism of Action: Hydralazine relaxes vascular smooth muscle, resulting in peripheral vasodilation and decreased systemic vascular resistance.
  + Dosing: The initial intravenous dose is typically 5-10 mg, with repeat doses given every 20-30 minutes as needed. The maximum cumulative dose is 30 mg.
  + Side Effects: Common side effects include tachycardia, headache, flushing, and palpitations. It should be used cautiously in patients with coronary artery disease or systemic lupus erythematosus.
  + Monitoring Parameters: Blood pressure, heart rate, and signs of hypotension should be closely monitored.
  + Clinical Pearls: Hydralazine can be used orally for maintenance therapy to control blood pressure.

Alternative Therapies:

1. Nifedipine:

* Mechanism of Action: Nifedipine is a calcium channel blocker that inhibits calcium influx into smooth muscle cells, resulting in vasodilation.
* Dosing: Immediate-release nifedipine can be given orally as 10-20 mg every 4-6 hours, up to a maximum of 120 mg per day. Extended-release formulations are also available.
* Side Effects: Common side effects include headache, flushing, dizziness, and peripheral edema. It should be used cautiously in patients with congestive heart failure or hypotension.
* Monitoring Parameters: Blood pressure, heart rate, and signs of hypotension should be closely monitored.
* Clinical Pearls: Nifedipine is not recommended for acute blood pressure control in hypertensive emergencies due to the risk of profound hypotension.

1. Methyldopa:

* Mechanism of Action: Methyldopa is an alpha-2 adrenergic agonist that reduces sympathetic outflow, leading to decreased peripheral vascular resistance and blood pressure.
* Dosing: The typical oral dose is 250-500 mg two to three times daily, with a maximum dose of 3 grams per day.
* Side Effects: Common side effects include drowsiness, dry mouth, and orthostatic hypotension. It should be used cautiously in patients with liver disease.
* Monitoring Parameters: Blood pressure, liver function tests, and signs of hypotension should be closely monitored.
* Clinical Pearls: Methyldopa is considered safe for use during pregnancy and is often used as a first-line antihypertensive agent.

Non-Pharmacological Interventions:

1. Bed Rest and Activity Restriction:

* Bed rest and reduced physical activity may be recommended in severe cases to help lower blood pressure and prevent complications. However, the evidence supporting the efficacy of strict bed rest is limited,and it may have negative effects on the patient's psychological well-being and physical conditioning.

1. Hydration and Nutrition:

* Adequate hydration and a well-balanced diet are important for overall maternal health. Patients should be encouraged to maintain proper fluid intake and consume a diet rich in fruits, vegetables, and lean proteins.

1. Regular Prenatal Care and Monitoring:

* Close follow-up with healthcare providers for regular prenatal care is crucial to monitor blood pressure, proteinuria, fetal growth, and maternal well-being. This allows for early detection of complications and timely intervention.

Clinical Pearls:

* Individualized management is essential based on the severity of the disease, gestational age, fetal well-being, and maternal condition.
* Multidisciplinary care involving obstetricians, maternal-fetal medicine specialists, and pharmacists is crucial for optimal management.
* Patient education plays a vital role in ensuring medication adherence, recognizing signs of worsening symptoms, and understanding the importance of regular prenatal visits.

In summary, the management of preeclampsia and eclampsia involves a combination of pharmacotherapy and non-pharmacological interventions. Magnesium sulfate is the first-line therapy for seizure prevention, while antihypertensive medications such as labetalol, hydralazine, nifedipine, and methyldopa are used to control blood pressure. Non-pharmacological interventions, including bed rest and hydration, complement the pharmacotherapy. Close monitoring, individualized care, and regular prenatal visits are essential for optimizing outcomes for both the mother and the fetus.

**Key Guidelines and Evidence**

Several organizations have published clinical practice guidelines on the management of hypertensive disorders in pregnancy, including preeclampsia and eclampsia:

* American College of Obstetricians and Gynecologists (ACOG)
* Society of Obstetric Medicine of Australia and New Zealand (SOMANZ)
* National Institute for Health and Care Excellence (NICE)
* American Heart Association (AHA)
* The International Society for the Study of Hypertension in Pregnancy (ISSHP)

While some variability exists between guidelines, there is general consensus on several key management principles:

* Blood pressure thresholds for treatment
* Antihypertensive agents of choice
* Magnesium sulfate for seizure prophylaxis
* Delivery considerations

A few areas of controversy include:

* Timing of delivery in preterm preeclampsia
* Target blood pressure goals during treatment
* Role for prophylactic magnesium sulfate

Table 1 summarizes the guideline recommendations most relevant to pharmacy management of preeclampsia/eclampsia.

Table 1. Guideline Recommendations for Management of Preeclampsia/Eclampsia

* Antihypertensive treatment should be initiated expeditiously for acute-onset severe hypertension (systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 110mmHg or more, or both) that is confirmed as persistent (15 minutes or more).The available literature suggests that antihypertensive agents should be administered within 30–60 minutes.
* Magnesium sulfate should be used for the prevention and treatment of seizures in women with gestational hypertension and preeclampsia with severe features or eclampsia.
* Non-steroidal anti-inflammatory medications should continue to be used preferentially over opioid analgesics.

| **Recommendation and Guideline(s)** | **Level of Evidence** | **Strength of Recommendation** |
| --- | --- | --- |
| Give magnesium sulfate for seizure prophylaxis in women with severe preeclampsia | I | A |
| Administer magnesium sulfate to treat eclamptic seizures | I | A |
| For severe hypertension (SBP ≥160 or DBP ≥110 mm Hg), give IV labetalol or IV hydralazine; oral nifedipine is second-line | I | A |
| In women with preeclampsia without severe features, delivery at 37 weeks is recommended | I | A |
| For preeclampsia with severe features <34 weeks, expectant management is often recommended if maternal and fetal condition allows | I | B |

Level of Evidence:  
I = Data derived from meta-analysis of multiple RCTs

Strength of Recommendation:  
A = Recommendation based on good and consistent scientific evidence  
B = Recommendation based on limited or inconsistent evidence

Clinical Trials and Evidence

Several landmark clinical trials have shaped the current management approach for preeclampsia and eclampsia:

* Magpie Trial: Showed that magnesium sulfate more than halved the risk of eclampsia recurrence compared to phenytoin or diazepam. This led to magnesium becoming the standard of care for seizure prophylaxis and treatment.
* MEXPRE Latin Study: Demonstrated that methyldopa is not superior to placebo for preventing preeclampsia in high-risk women, despite being commonly used for this indication.
* CHIPS Trial: Compared less tight (target diastolic BP 85-105 mm Hg) versus tight (target diastolic BP 85 mm Hg) blood pressure control in pregnant women with chronic or gestational hypertension. The less tight control group had fewer adverse maternal and fetal/neonatal outcomes. This trial has influenced blood pressure targets during treatment.
* HYPITAT-II Trial: Showed no significant difference in outcomes between induction of labor and expectant monitoring for women with gestational hypertension or preeclampsia near term (36-41 weeks). This provides support for delivery at 37 weeks for preeclampsia without severe features.

**Clinical Scenarios**

Scenario 1:  
A 32-year-old pregnant woman at 35 weeks' gestation presents to the emergency department with severe headache, visual disturbances, and epigastric pain. Her blood pressure is 160/100 mm Hg, and proteinuria is detected on urine dipstick. Upon further evaluation, laboratory tests reveal elevated liver enzymes and thrombocytopenia. The diagnosis of severe preeclampsia is made. However, the patient has a known allergy to labetalol, which is the first-line antihypertensive agent for preeclampsia.

Key Learning Point: Allergies to First-Line Medications in Preeclampsia Management

Management Considerations: In this scenario, the first-line antihypertensive agent for preeclampsia, labetalol, is contraindicated due to the patient's allergy. An alternative antihypertensive should be considered. Hydralazine can be used as an alternative agent for blood pressure control. The initial dose of hydralazine is typically 10-20 mg intravenously, followed by repeat doses if needed. Close monitoring of blood pressure and signs of hypotension is essential. It is important to communicate with the patient regarding the allergy and alternative medication choice.

Scenario 2:  
A 25-year-old primigravida woman at 32 weeks' gestation with a history of chronic hypertension presents with new-onset seizures and a blood pressure of 190/110 mm Hg. She is diagnosed with eclampsia.

Key Learning Point: Prompt Seizure Control in Eclampsia

Management Considerations: In this scenario, immediate seizure control is crucial to protect the mother and fetus. The initial management involves administering a loading dose of magnesium sulfate. A loading dose of 4-6 grams can be given intravenously over 15-20 minutes. Maintenance therapy with magnesium sulfate should be initiated at a rate of 1-2 grams per hour as an intravenous infusion. Blood pressure control with antihypertensive medications, such as labetalol or hydralazine, should also be initiated. Continuous monitoring of the patient's respiratory rate, blood pressure, reflexes, urine output, and magnesium levels is vital. Prompt delivery may be necessary if there is no improvement in the maternal condition or signs of fetal distress.

Scenario 3:  
A 38-year-old pregnant woman at 37 weeks' gestation is admitted to the labor and delivery unit with a diagnosis of severe preeclampsia. Her blood pressure is 160/100 mm Hg, and she has 3+ proteinuria. She complains of severe headache and blurred vision. Laboratory tests show normal liver enzymes and platelet counts.

Key Learning Point: Diagnosis of Severe Preeclampsia without End-Organ Damage

Management Considerations: In this scenario, the patient meets the criteria for severe preeclampsia based on blood pressure and proteinuria. However, there is no evidence of end-organ damage. This highlights the importance of considering other symptoms and laboratory findings to assess the severity of the condition. Close monitoring of the patient's symptoms, blood pressure, and fetal well-being is essential. Antihypertensive therapy should be initiated to control blood pressure. Magnesium sulfate can be considered for seizure prophylaxis. Delivery may be indicated if there is worsening of symptoms or signs of fetal compromise. Regular follow-up and close communication with the obstetric team are crucial for appropriate management.

**Tips for Board Exam Questions**

Here are 3 key tips for answering board certification exam questions on preeclampsia and eclampsia:

1. Know the diagnostic criteria for preeclampsia - new-onset hypertension after 20 weeks gestation plus one of the following: proteinuria, thrombocytopenia, impaired liver function, new development of renal insufficiency, pulmonary edema, or new-onset cerebral/visual disturbances.
2. Remember magnesium sulfate is the first-line agent for seizure prophylaxis and treatment in severe preeclampsia-eclampsia. Loading dose is 4-6 g IV followed by maintenance infusion.
3. For acute blood pressure management in severe hypertension, IV labetalol and hydralazine are preferred over oral agents. Treatment goal is to reduce BP but avoid too aggressive reduction as this can compromise uteroplacental perfusion.

Keeping these key facts in mind will help recognize the correct diagnosis, prioritize magnesium administration, and select appropriate pharmacotherapy when answering exam questions on hypertensive emergencies in pregnancy. Focusing on these fundamental principles will lead to the highest yield when tested on preeclampsia and eclampsia.

**Subtopic Summary**

Preeclampsia and eclampsia are serious conditions that require a comprehensive and multidisciplinary approach to management. Regular prenatal care and monitoring play a crucial role in detecting and diagnosing these conditions. Key learning points include the significance of regular blood pressure monitoring and urine protein testing in pregnant women. Elevated blood pressure and proteinuria are hallmark signs of preeclampsia and should prompt further evaluation and management.

Overall, a proactive and collaborative approach is key to effectively managing preeclampsia and eclampsia, with a focus on early detection, prompt intervention, and close monitoring of both maternal and fetal well-being.

**References and Bibliography**

1. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131. doi:10.1097/01.AOG.0000437382.03963.88
2. Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(1):11-16. doi:10.1111/ajo.12294
3. Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-1890. doi:10.1016/S0140-6736(02)08778-0
4. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-417. doi:10.1056/NEJMoa1404595
5. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al; HYPITAT II study group. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet. 2015;385(9986):2492-2501. doi:10.1016/S0140-6736(14)61998-X
6. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. 2019. Accessed March 1, 2023. <https://www.nice.org.uk/guidance/ng133>
7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020 Jun;135(6):e237-e260. doi: 10.1097/AOG.0000000000003891. PMID: 32443079.
8. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. doi:10.1002/14651858.CD000025.pub2
9. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;2013(7):CD001449. doi:10.1002/14651858.CD001449.pub3
10. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105-145. doi:10.1016/j.preghy.2014.01.003
11. Benninger C. Pre-eclampsia: definitions, evidence-based diagnoses, and future directions. Front Immunol. 2020;11:982. doi:10.3389/fimmu.2020.00982

**Clinical Scenarios**

Scenario 1:  
A 32-year-old pregnant woman at 35 weeks' gestation presents to the emergency department with severe headache, visual disturbances, and epigastric pain. Her blood pressure is 160/100 mm Hg, and proteinuria is detected on urine dipstick. Upon further evaluation, laboratory tests reveal elevated liver enzymes and thrombocytopenia. The diagnosis of severe preeclampsia is made. However, the patient has a known allergy to labetalol, which is the first-line antihypertensive agent for preeclampsia.

Key Learning Point: Allergies to First-Line Medications in Preeclampsia Management

Management Considerations: In this scenario, the first-line antihypertensive agent for preeclampsia, labetalol, is contraindicated due to the patient's allergy. An alternative antihypertensive should be considered. Hydralazine can be used as an alternative agent for blood pressure control. The initial dose of hydralazine is typically 10-20 mg intravenously, followed by repeat doses if needed. Close monitoring of blood pressure and signs of hypotension is essential. It is important to communicate with the patient regarding the allergy and alternative medication choice.

Scenario 2:  
A 25-year-old primigravida woman at 32 weeks' gestation with a history of chronic hypertension presents with new-onset seizures and a blood pressure of 190/110 mm Hg. She is diagnosed with eclampsia.

Key Learning Point: Prompt Seizure Control in Eclampsia

Management Considerations: In this scenario, immediate seizure control is crucial to protect the mother and fetus. The initial management involves administering a loading dose of magnesium sulfate. A loading dose of 4-6 grams can be given intravenously over 15-20 minutes. Maintenance therapy with magnesium sulfate should be initiated at a rate of 1-2 grams per hour as an intravenous infusion. Blood pressure control with antihypertensive medications, such as labetalol or hydralazine, should also be initiated. Continuous monitoring of the patient's respiratory rate, blood pressure, reflexes, urine output, and magnesium levels is vital. Prompt delivery may be necessary if there is no improvement in the maternal condition or signs of fetal distress.

Scenario 3:  
A 38-year-old pregnant woman at 37 weeks' gestation is admitted to the labor and delivery unit with a diagnosis of severe preeclampsia. Her blood pressure is 160/100 mm Hg, and she has 3+ proteinuria. She complains of severe headache and blurred vision. Laboratory tests show normal liver enzymes and platelet counts.

Key Learning Point: Diagnosis of Severe Preeclampsia without End-Organ Damage

Management Considerations: In this scenario, the patient meets the criteria for severe preeclampsia based on blood pressure and proteinuria. However, there is no evidence of end-organ damage. This highlights the importance of considering other symptoms and laboratory findings to assess the severity of the condition. Close monitoring of the patient's symptoms, blood pressure, and fetal well-being is essential. Antihypertensive therapy should be initiated to control blood pressure. Magnesium sulfate can be considered for seizure prophylaxis. Delivery may be indicated if there is worsening of symptoms or signs of fetal compromise. Regular follow-up and close communication with the obstetric team are crucial for appropriate management.

**Tips for Board Exam Questions**

Here are 3 key tips for answering board certification exam questions on preeclampsia and eclampsia:

1. Know the diagnostic criteria for preeclampsia - new-onset hypertension after 20 weeks gestation plus one of the following: proteinuria, thrombocytopenia, impaired liver function, new development of renal insufficiency, pulmonary edema, or new-onset cerebral/visual disturbances.
2. Remember magnesium sulfate is the first-line agent for seizure prophylaxis and treatment in severe preeclampsia-eclampsia. Loading dose is 4-6 g IV followed by maintenance infusion.
3. For acute blood pressure management in severe hypertension, IV labetalol and hydralazine are preferred over oral agents. Treatment goal is to reduce BP but avoid too aggressive reduction as this can compromise uteroplacental perfusion.

Keeping these key facts in mind will help recognize the correct diagnosis, prioritize magnesium administration, and select appropriate pharmacotherapy when answering exam questions on hypertensive emergencies in pregnancy. Focusing on these fundamental principles will lead to the highest yield when tested on preeclampsia and eclampsia.

**Subtopic Summary**

Preeclampsia and eclampsia are serious conditions that require a comprehensive and multidisciplinary approach to management. Regular prenatal care and monitoring play a crucial role in detecting and diagnosing these conditions. Key learning points include the significance of regular blood pressure monitoring and urine protein testing in pregnant women. Elevated blood pressure and proteinuria are hallmark signs of preeclampsia and should prompt further evaluation and management.

Prompt control of seizures is crucial in the management of eclampsia. Magnesium sulfate is the drug of choice for seizure prophylaxis and treatment. It is administered intravenously and requires close monitoring of respiratory rate, blood pressure, reflexes, urine output, and magnesium levels.

First-line antihypertensive agents, such as labetalol and hydralazine, are commonly used for blood pressure control in preeclampsia. Alternative options, like nifedipine and methyldopa, are available for patients with contraindications or allergies to first-line medications. Close monitoring of blood pressure, heart rate, and signs of hypotension is essential during antihypertensive therapy.

Individualized management plans should be developed based on the severity of the disease, gestational age, and fetal well-being. Collaboration among obstetricians, maternal-fetal medicine specialists, pharmacists, and other healthcare providers is crucial to ensure optimal management and outcomes.

Patient education is vital in promoting medication adherence, recognizing signs of worsening symptoms, and understanding the importance of regular prenatal visits. Timely delivery may be necessary in severe cases or when there are signs of fetal distress. Regular follow-up visits and ongoing monitoring are essential to detect any changes in the condition and adjust management accordingly.

Overall, a proactive and collaborative approach is key to effectively managing preeclampsia and eclampsia, with a focus on early detection, prompt intervention, and close monitoring of both maternal and fetal well-being.

**References and Bibliography**

1. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131. doi:10.1097/01.AOG.0000437382.03963.88
2. Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(1):11-16. doi:10.1111/ajo.12294
3. Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-1890. doi:10.1016/S0140-6736(02)08778-0
4. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-417. doi:10.1056/NEJMoa1404595
5. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al; HYPITAT II study group. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet. 2015;385(9986):2492-2501. doi:10.1016/S0140-6736(14)61998-X
6. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. 2019. Accessed March 1, 2022. <https://www.nice.org.uk/guidance/ng133>
7. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):e1-e25. doi:10.1097/AOG.0000000000003018
8. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. doi:10.1002/14651858.CD000025.pub2
9. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;2013(7):CD001449. doi:10.1002/14651858.CD001449.pub3
10. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105-145. doi:10.1016/j.preghy.2014.01.003
11. Benninger C. Pre-eclampsia: definitions, evidence-based diagnoses, and future directions. Front Immunol. 2020;11:982. doi:10.3389/fimmu.2020.00982